In-vitro synergistic activity of the combination of ampicillin and arbekacin against vancomycin-and high-level gentamicin-resistant Enterococcus faecium with the aph(2")-Id gene.
The combination of ampicillin plus arbekacin produced synergistic killing against 8 of 13 vancomycin-, ampicillin-, gentamicin-, and streptomycin-resistant Enterococcus faecium isolates that possess the high-level gentamicin resistance gene, aph(2")-Id. This combination may prove useful in treating infections caused by multiresistant enterococci.
Kak
V
V
Research and Medical Service, John D Dingell VA Medical Center, and Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI 48201, USA.
You
I
I
Zervos
M J
MJ
Kariyama
R
R
Kumon
H
H
Chow
J W
JW
D000617:Aminoglycosides; D000667:Ampicillin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins; D004269:DNA, Bacterial / Q000032:analysis; D003982:Dibekacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D016984:Enterococcus faecium / Q000187:drug effects* / Q000235:genetics; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics*; D016133:Polymerase Chain Reaction; D013307:Streptomycin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D005839:Gentamicins; D003982:Dibekacin; D014640:Vancomycin; D000667:Ampicillin; C112789:APH(2'')-Id protein, Enterococcus; D017853:Phosphotransferases (Alcohol Group Acceptor); C031986:arbekacin; D013307:Streptomycin